Collins Helen Louise — SEC insider filings
SEC reporting owner CIK 1701247. 34 insider filings on record with FilingPulse; latest filed 2026-11-19.
Transaction summary — filings shown
Covers all 34 filings on record, filed 2020-08-24 to 2026-11-19. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 29 legs across 14 filings — 190,816 shares, $6,340,228 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 65.
- Largest priced transaction: sale of 40,000 shares @ $35.10 ($1,404,024) in Enliven Therapeutics, Inc., filed 2026-03-27.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | CHIEF MEDICAL OFFICER | 19 | — | 29 legs · 190,816 sh · $6,340,228 | 36 |
| FIVE PRIME THERAPEUTICS, INC. (FPRX) | EVP and Chief Medical Officer | 6 | — | — | 19 |
| Kura Oncology, Inc. (KURA) | Director | 6 | — | — | 7 |
| IO Biotech, Inc. (IOBT) | Director | 3 | — | — | 3 |
Insider filings — Collins Helen Louise
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-19 | 4 | Enliven Therapeutics, Inc. (ELVN) | Option exercise (M): 5,000 @ $2.48 · Sale (S): 4,939 @ $46.83 · Sale (S): 61 @ $47.60 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2026-10-21 | 4 | Enliven Therapeutics, Inc. (ELVN) | Option exercise (M): 5,000 @ $2.48 · Sale (S): 5,000 @ $38.47 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2026-09-21 | 4 | Enliven Therapeutics, Inc. (ELVN) | Option exercise (M): 5,000 @ $2.48 · Sale (S): 2,916 @ $50.03 · Sale (S): 1,844 @ $50.71 · Sale (S): 240 @ $51.48 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2026-08-19 | 4 | Enliven Therapeutics, Inc. (ELVN) | Option exercise (M): 5,000 @ $2.48 · Sale (S): 3,900 @ $58.37 · Sale (S): 1,100 @ $59.35 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2026-07-21 | 4 | Enliven Therapeutics, Inc. (ELVN) | Option exercise (M): 5,000 @ $2.48 · Sale (S): 231 @ $50.05 · Sale (S): 459 @ $51.55 · Sale (S): 2,063 @ $52.39 · Sale (S): 2,184 @ $53.42 · Sale (S): 63 @ $53.92 · +1 more | EDGAR |
| 2026-06-22 | 4 | Enliven Therapeutics, Inc. (ELVN) | Option exercise (M): 5,000 @ $2.48 · Sale (S): 1,268 @ $42.83 · Sale (S): 2,599 @ $43.87 · Sale (S): 1,133 @ $44.74 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | Kura Oncology, Inc. (KURA) | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2026-05-20 | 4 | Enliven Therapeutics, Inc. (ELVN) | Option exercise (M): 5,000 @ $2.48 · Sale (S): 3,475 @ $39.53 · Sale (S): 1,302 @ $40.25 · Sale (S): 223 @ $41.21 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2026-04-21 | 4 | Enliven Therapeutics, Inc. (ELVN) | Option exercise (M): 5,000 @ $2.48 · Sale (S): 140 @ $45.81 · Sale (S): 2,419 @ $47.39 · Sale (S): 2,441 @ $48.06 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2026-03-27 | 4 | Enliven Therapeutics, Inc. (ELVN) | Option exercise (M): 40,000 @ $2.48 · Sale (S): 40,000 @ $35.10 · Option exercise (M): 40,000 (derivative) @ $0 | EDGAR |
| 2026-03-19 | 4 | Enliven Therapeutics, Inc. (ELVN) | Option exercise (M): 5,000 @ $2.48 · Sale (S): 5,000 @ $27.76 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2026-03-11 | 4 | Enliven Therapeutics, Inc. (ELVN) | Option exercise (M): 29,871 @ $2.48 · Sale (S): 29,871 @ $30.02 · Option exercise (M): 10,129 @ $2.48 · Sale (S): 10,129 @ $30.19 · Option exercise (M): 29,871 (derivative) @ $0 · Option exercise (M): 10,129 (derivative) @ $0 | EDGAR |
| 2026-02-19 | 4 | Enliven Therapeutics, Inc. (ELVN) | Option exercise (M): 45,000 @ $2.48 · Sale (S): 45,000 @ $26.17 · Option exercise (M): 45,000 (derivative) @ $0 | EDGAR |
| 2026-02-17 | 4 | Enliven Therapeutics, Inc. (ELVN) | Grant/award (A): 25,000 @ $0 · Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | Kura Oncology, Inc. (KURA) | Grant/award (A): 28,500 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | IO Biotech, Inc. (IOBT) | Grant/award (A): 35,144 (derivative) @ $0 | EDGAR |
| 2025-02-10 | 4 | Enliven Therapeutics, Inc. (ELVN) | Grant/award (A): 171,000 (derivative) @ $0 | EDGAR |
| 2024-10-22 | 4 | Enliven Therapeutics, Inc. (ELVN) | Option exercise (M): 816 @ $2.48 · Sale (S): 816 @ $30.00 · Option exercise (M): 816 (derivative) @ $0 | EDGAR |
| 2024-06-07 | 4 | Kura Oncology, Inc. (KURA) | Grant/award (A): 26,000 (derivative) @ $0 | EDGAR |
| 2024-06-07 | 4 | IO Biotech, Inc. (IOBT) | Grant/award (A): 45,642 (derivative) @ $0 | EDGAR |
| 2024-04-15 | 4 | Enliven Therapeutics, Inc. (ELVN) | Option exercise (M): 20,000 @ $2.48 · Sale (S): 20,000 @ $25.07 · Option exercise (M): 20,000 (derivative) @ $0 | EDGAR |
| 2024-02-15 | 4 | Enliven Therapeutics, Inc. (ELVN) | Grant/award (A): 185,000 (derivative) @ $0 | EDGAR |
| 2023-11-17 | 4 | IO Biotech, Inc. (IOBT) | Grant/award (A): 64,238 (derivative) @ $0 | EDGAR |
| 2023-06-02 | 4 | Kura Oncology, Inc. (KURA) | Grant/award (A): 26,000 (derivative) @ $0 | EDGAR |
| 2023-04-06 | 4 | Enliven Therapeutics, Inc. (ELVN) | Grant/award (A): 206,000 (derivative) @ $0 | EDGAR |
| 2023-02-27 | 4 | Enliven Therapeutics, Inc. (ELVN) | Grant/award (A): 287,084 (derivative) | EDGAR |
| 2022-06-23 | 4 | Kura Oncology, Inc. (KURA) | Grant/award (A): 23,000 (derivative) @ $0 | EDGAR |
| 2021-07-29 | 4 | Kura Oncology, Inc. (KURA) | Grant/award (A): 46,000 (derivative) @ $0 · Grant/award (A): 19,166 (derivative) @ $0 | EDGAR |
| 2021-04-19 | 4 | FIVE PRIME THERAPEUTICS, INC. (FPRX) | Gift (G): 8,085 @ $0 · Grant/award (A): 66,000 @ $0 · Disposition to issuer (D): 135,547 @ $38 · Disposition to issuer (D): 60,000 (derivative) · Disposition to issuer (D): 50,000 (derivative) · Disposition to issuer (D): 58,000 (derivative) · +3 more | EDGAR |
| 2021-03-02 | 4 | FIVE PRIME THERAPEUTICS, INC. (FPRX) | Tax withholding (F): 1,158 @ $22.23 | EDGAR |
| 2021-02-26 | 4 | FIVE PRIME THERAPEUTICS, INC. (FPRX) | Tax withholding (F): 5,091 @ $25.71 · Tax withholding (F): 1,653 @ $23.08 | EDGAR |
| 2020-12-15 | 4 | FIVE PRIME THERAPEUTICS, INC. (FPRX) | Option exercise (M): 22,000 @ $0 · Tax withholding (F): 11,583 @ $16.14 · Option exercise (M): 22,000 (derivative) @ $0 | EDGAR |
| 2020-11-13 | 4 | FIVE PRIME THERAPEUTICS, INC. (FPRX) | Option exercise (M): 22,000 @ $0 · Tax withholding (F): 11,039 @ $18 · Option exercise (M): 22,000 (derivative) @ $0 | EDGAR |
| 2020-08-24 | 4 | FIVE PRIME THERAPEUTICS, INC. (FPRX) | Tax withholding (F): 827 @ $4.69 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-08-18 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1701247 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs